In a report released on November 7, Luca Issi from RBC Capital maintained a Buy rating on Caribou Biosciences (CRBU – Research Report), with a price target of $19.00. The company’s shares closed yesterday at $4.53.
Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BioMarin Pharmaceutical, and Ionis Pharmaceuticals. According to TipRanks, Issi has an average return of -29.6% and a 15.79% success rate on recommended stocks.
In addition to RBC Capital, Caribou Biosciences also received a Buy from Evercore ISI’s Liisa Bayko in a report issued on October 31. However, yesterday, Cantor Fitzgerald initiated coverage with a Hold rating on Caribou Biosciences (NASDAQ: CRBU).
See Insiders’ Hot Stocks on TipRanks >>
Based on Caribou Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $3.76 million and a GAAP net loss of $29.52 million. In comparison, last year the company earned a revenue of $4.19 million and had a GAAP net loss of $26.7 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caribou Biosciences (CRBU) Company Description:
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
Read More on CRBU:
- Caribou Biosciences appoints Sundar Jagannath, MD to Scientific Advisory Board
- Caribou Biosciences reports Q3 EPS (12c), consensus (42c)
- Caribou Biosciences appoints Sundar Jagannath to Scientific Advisory Board
- Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
- Caribou Biosciences to Participate in Upcoming Investor Conferences
